INmune Bio's AD02 trial for Alzheimer's disease, using TNF XPro with EMACC as the primary endpoint, shows positive results after FDA clinical hold. The trial's efficacy in assessing cognitive function in early Alzheimer's stages is validated, advancing potential treatment options.